9) Multiagent Medical Countermeasures
Abstract
Continues efforts previously funded under the Transformational Medical Technologies Initiative to develop candidate countermeasures for Hemorrhagic Fever Virus (HFV) and Intracellular Bacterial Pathogen (IBP). Focuses on the initiation and completion of preclinical studies for candidate countermeasures, to include safety, toxicity, efficacy, and scalability work in accordance with the product's intended use. The ability to formulate Good Manufacturing Practices (GMP), pilot lots and further mature promising drug candidates will be the focus of activities in this capability area. The preclinical drug discovery process culminates in the submission of an Investigational New Drug (IND) application to the Food and Drug Administration (FDA), to determine if candidate countermeasures are suitable for safety evaluation in humans.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2015
- Source ID
- 1db50cdb4e020573d30fa0f645e7a166